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Sir,
The proto-oncogene ras is mutated in 20% of lung cancer
(Mascaux et al, 2005). Among 36 patients with primary operable
non-small-cell lung cancer (NSCLC), we detected seven (19.4%)
with K-ras exon I mutations on tumour samples (Ferretti et al,
2000). However, the prognostic significance of ras for survival in
this disease remains controversial.
Aggregating data obtained by univariate analysis in retro-
spective trials, ras gene alteration appears to be a poor prognostic
factor for survival in NSCLC (Mascaux et al, 2005). The authors
concluded that ras appears to be a pejorative prognostic factor in
terms of survival in NSCLC globally, in adenocarcinomas and
when it is studied by polymerase chain reaction. In 44 patients
with stage III NSCLC undergoing tumour resection after neoadju-
vant treatment, the presence of a ras mutation, which was found
independently of gender, age, tumour stage and clinical response
status, was a significant predictor for a poor progression-
free survival even after complete resection (Broermann et al,
2002). Patients with K-ras mutant NSCLC showed poorer
clinical outcomes when treated with erlotinib and chemotherapy
(Eberhard et al, 2005). Furthermore, in NSCLCs with ras mutation,
the overexpression of Skp2, a protein that plays a critical role in
cell cycle progression, was a significant independent poor
prognostic marker of survival (Zhu et al, 2004).
By contrast, in the adjuvant setting, among 227 patients with
surgically resected NSCLC, the K-ras mutations (codons 1–31)
were not predictive markers of a shorter survival (Moldvay et al,
2000). Other authors had previously shown only a trend toward
improved survival for patients with wild-type ras compared with
those with mutant ras who were randomised to receive adjuvant
postoperative radiotherapy or radiotherapy plus concurrent
chemotherapy (Schiller et al, 2001). At the multivariate analysis,
a trend bordering on statistical significance for K-ras was
registered as well. However, according to Winton et al (2005), in
patients with completely resected stage IB–II NSCLC, adjuvant
chemotherapy did not confer a survival advantage in those whose
tumours had ras mutations, whereas it did in patients with wild-
type ras. It must be highlighted that in this study the interaction
analysis showed that the effect of ras mutations on the treatment
outcome was not statistically significant.
Thus, in order to stratify variables for future treatment
approaches, the prognostic and predictive impact of ras mutation
status still needs to be confirmed in prospective trials with
appropriate multivariate analysis.
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